Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-04-25 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于子公司2022年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement (680 characters) regarding the completion of a restricted stock incentive plan's first vesting period for a subsidiary, including changes in share capital and shareholding percentages. It references a related announcement on the Shanghai Stock Exchange website but does not contain detailed financial statements or comprehensive report data. The content focuses on shareholding changes due to stock incentives and their impact on control and financial consolidation. This fits best under Share Issue/Capital Change (SHA) as it deals with changes in share capital and ownership structure due to stock incentives. The document is not a full financial report, earnings release, or management discussion, nor is it a regulatory certification or voting result. Therefore, the classification is SHA with high confidence.
2024-04-25 Chinese
关于子公司鼻喷流感减毒活疫苗上市许可申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Changchun High-tech Industry Group Co., Ltd. regarding the acceptance of a subsidiary's application for marketing authorization of a nasal spray influenza live attenuated vaccine by the National Medical Products Administration. It includes a disclaimer about the authenticity of the information and notes that the acceptance does not have a significant impact on recent performance. The document does not contain financial data, detailed financial results, or management discussion. It is an announcement about regulatory progress related to a product approval, not a financial report or detailed management report. The length is short (696 characters), and it is clearly an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS).
2024-04-23 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "长春高新技术产业（集团）股份有限公司2024 年第一季度报告" which translates to "Changchun High-tech Industry (Group) Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the first quarter of 2024. It explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. The document is not an announcement or a certification but the actual report itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-19 Chinese
关于子公司注射用醋酸曲普瑞林微球上市申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High & New Technology Industry Group Co., Ltd. regarding the acceptance of a subsidiary's drug listing application by the National Medical Products Administration. It details the drug's basic information, the acceptance notice, potential impact on the company, and risk warnings. The document is short (879 characters) and serves as a regulatory announcement about a product approval process, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report itself but an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-18 Chinese
关于2022年限制性股票与股票期权激励计划部分股票期权注销完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of part of the company's stock options under a 2022 restricted stock and stock option incentive plan. It details the board meeting resolutions, compliance with regulatory requirements, and confirms that the cancellation has been completed. There is no financial statement or detailed financial analysis present. The document is a formal announcement about a capital-related event (stock option cancellation) but explicitly states it does not affect the company's capital structure. This fits best under the category of Share Issue/Capital Change announcements, which include stock option cancellations and related capital changes. The document length is short and focused on a specific corporate action rather than a full report or financial disclosure, so it is not an Annual Report, Interim Report, or similar. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-04-15 Chinese
关于子公司注射用金纳单抗上市申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High & New Technology Industry Group Co., Ltd. regarding the acceptance of a listing application for a subsidiary's drug product by the National Medical Products Administration. It details the drug's basic information, regulatory acceptance notice, potential impact on the company, and risk warnings. The document is short (952 characters) and serves as a regulatory announcement about a drug approval process, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report itself but an official announcement of a regulatory acceptance event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.